Truvada News and Research

RSS
Schering-Plough expands Vicriviroc study in treatment-naive patients with HIV

Schering-Plough expands Vicriviroc study in treatment-naive patients with HIV

Gilead Sciences announces notification of ANDA filing for Atripla

Gilead Sciences announces notification of ANDA filing for Atripla

Mylan's Matrix receives tentative FDA approval under PEPFAR for generic Truvada

Mylan's Matrix receives tentative FDA approval under PEPFAR for generic Truvada

Gilead initiates phase III trial of Elvitegravir

Gilead initiates phase III trial of Elvitegravir

Researchers to compare common ARV as a pill and vaginal gel in unique HIV prevention study

Researchers to compare common ARV as a pill and vaginal gel in unique HIV prevention study

Boehringer, Gilead freeze antiretroviral prices for some U.S. agencies

Boehringer, Gilead freeze antiretroviral prices for some U.S. agencies

U.S. PTO's rejection of Gilead's antiretroviral patents might affect applications in India

U.S. PTO's rejection of Gilead's antiretroviral patents might affect applications in India

Merck to register, lower cost of antiretroviral Atripla in developing countries

Merck to register, lower cost of antiretroviral Atripla in developing countries

FDA approves Atripla for the treatment of HIV-1 infection in adults

FDA approves Atripla for the treatment of HIV-1 infection in adults

Approval of fixed-dose combination treatments for HIV-1 infection

Approval of fixed-dose combination treatments for HIV-1 infection

FDA approves two fixed-dose combination treatments for HIV-1 infection

FDA approves two fixed-dose combination treatments for HIV-1 infection